Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst. Billionaire Investor Bill Ackman Just Went All In On One of His Favorite Stocks: He Plans to Hold It ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed as inflation drops. In a fresh appearance on CNBC’s ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...